PURPOSE Hand-foot syndrome (HFS) is a typical skin disorder caused by the use of cytotoxic anticancer drugs and molecular targets. Similarly, various anticancer drugs have been used as a conditioning regimen for hematopoietic stem cell transplantation (HSCT), and skin disorders such as HFS have been reported. The aim of this study was to determine retrospectively the frequency of HFS in recipients who have received a first allogeneic HSCT and the risk factors for HFS occurrence. METHODS We retrospectively investigated the medical records of recipients who received their first allogeneic HSCT and neutrophil engraftment at Shizuoka Cancer Center from January 1, 2011, to December 31, 2019. RESULTS The occurrence of HFS was confirmed in 78 cases (48.1%), and no grade 3 HFS was confirmed. The median occurrence of HFS was 8 (- 3 to 19) days. In recipients with and without confirmed HFS, the median neutrophil engraftment day was 16.5 (10-33) and 15.0 (11-26) days, respectively (p = 0.013). Multivariate analysis indicated that the frequency of HFS was statistically significantly higher in women (p = 0.032), recipients administered busulfan (Bu) four times daily (p = 0.011), and recipients previously treated with anthracycline (p = 0.002). CONCLUSION Attention should be paid to HFS that occurs due to the conditioning regimen for HSCT in women, recipients who received 0.8 mg/kg of Bu four times a day, and recipients with a history of anthracycline administration, as HFS may affect the duration to neutrophil engraftment.

中文翻译：

---

造血干细胞移植受者手足综合征及危险因素[J].

目的 手足综合征 (HFS) 是由使用细胞毒性抗癌药物和分子靶点引起的典型皮肤病。同样，各种抗癌药物已被用作造血干细胞移植 (HSCT) 的预处理方案，并且已经报道了 HFS 等皮肤疾病。本研究的目的是回顾性确定接受第一次同种异体 HSCT 的受者中 HFS 的频率以及 HFS 发生的危险因素。方法 回顾性调查 2011 年 1 月 1 日至 2019 年 12 月 31 日在静冈县癌症中心接受首次异基因 HSCT 和中性粒细胞移植的受者病历。结果 78 例（48.1%）确诊 HFS，未确认 3 级 HFS。HFS 的中位发生时间为 8（- 3 至 19）天。在确诊和未确诊 HFS 的受者中，中性粒细胞植入天数中位数分别为 16.5 (10-33) 和 15.0 (11-26) 天 (p = 0.013)。多变量分析表明，女性 (p = 0.032)、接受白消安 (Bu) 每天四次 (p = 0.011) 的接受者和先前接受过蒽环类药物治疗的接受者 (p = 0.002) 的 HFS 频率在统计学上显着更高。结植入。多变量分析表明，女性 (p = 0.032)、接受白消安 (Bu) 每天四次 (p = 0.011) 的接受者和先前接受过蒽环类药物治疗的接受者 (p = 0.002) 的 HFS 频率在统计学上显着更高。结植入。多变量分析表明，女性 (p = 0.032)、接受白消安 (Bu) 每天四次 (p = 0.011) 的接受者和先前接受过蒽环类药物治疗的接受者 (p = 0.002) 的 HFS 频率在统计学上显着更高。结植入。